Literature DB >> 20151336

Stability of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in combination.

Duoli Guo1, Paul B Myrdal, Kelly L Karlage, Sean P O'Connell, Travis J Wissinger, S Esmail Tabibi, Samuel H Yalkowsky.   

Abstract

In vivo, the DNA methyltransferase inhibitor, 5-fluoro-2'-deoxycytidine (FdCyd, NSC-48006), is rapidly converted to its unwanted metabolites. Tetrahydrouridine (THU, NSC-112907), a cytidine deaminase inhibitor can block the first metabolic step in FdCyd catabolism. Clinical studies have shown that co-administration with THU can inhibit the metabolism of FdCyd. The National Cancer Institute is particularly interested in a 1:5 FdCyd/THU formulation. The purpose of this study was to investigate the in vitro pH stability of FdCyd and THU individually and in combination. A stability-indicating high-performance liquid chromatography method for the quantification of both compounds and their degradants was developed using a ZIC(R)-HILIC column. The effect of THU and FdCyd on the in vitro degradation of each other was studied as a function of pH from 1.0 to 7.4 in aqueous solutions at 37 degrees C. The degradation of FdCyd appears to be first-order and acid-catalyzed. THU equilibrates with at least one of its degradants. The combination of FdCyd and THU in solution does not affect the stability of either compound. The stability and compatibility of FdCyd and THU in the solid state at increased relative humidity and at various temperatures are also evaluated.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20151336      PMCID: PMC2850501          DOI: 10.1208/s12249-010-9383-2

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  5 in total

1.  Analysis of cytidine deaminase and tetrahydrouridine interaction by use of ligand techniques.

Authors:  R G Stoller; C E Myers; B A Chabner
Journal:  Biochem Pharmacol       Date:  1978-01-01       Impact factor: 5.858

2.  Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice.

Authors:  Jan H Beumer; Julie L Eiseman; Robert A Parise; Erin Joseph; Julianne L Holleran; Joseph M Covey; Merrill J Egorin
Journal:  Clin Cancer Res       Date:  2006-11-30       Impact factor: 12.531

3.  Epimer interconversion, isomerization, and hydrolysis of tetrahydrouridine: implications for cytidine deaminase inhibition.

Authors:  Tian-Xiang Xiang; Riku Niemi; Paul Bummer; Bradley D Anderson
Journal:  J Pharm Sci       Date:  2003-10       Impact factor: 3.534

4.  Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).

Authors:  Jan H Beumer; Robert A Parise; Edward M Newman; James H Doroshow; Timothy W Synold; Heinz-Josef Lenz; Merrill J Egorin
Journal:  Cancer Chemother Pharmacol       Date:  2007-09-26       Impact factor: 3.333

5.  Tumor-selective metabolism of 5-fluoro-2'-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil in mice bearing Lewis lung carcinoma.

Authors:  D A Boothman; T V Briggle; S Greer
Journal:  Cancer Res       Date:  1987-05-01       Impact factor: 12.701

  5 in total
  5 in total

Review 1.  The Emerging Role of Cytidine Deaminase in Human Diseases: A New Opportunity for Therapy?

Authors:  Audrey Frances; Pierre Cordelier
Journal:  Mol Ther       Date:  2019-12-06       Impact factor: 11.454

Review 2.  DNA methylation profiles in cancer diagnosis and therapeutics.

Authors:  Yunbao Pan; Guohong Liu; Fuling Zhou; Bojin Su; Yirong Li
Journal:  Clin Exp Med       Date:  2017-07-27       Impact factor: 3.984

3.  Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels.

Authors:  Naotake Funamizu; Curtis Ray Lacy; Kaori Fujita; Kenei Furukawa; Takeyuki Misawa; Katsuhiko Yanaga; Yoshinobu Manome
Journal:  PLoS One       Date:  2012-05-16       Impact factor: 3.240

Review 4.  Digging deep into "dirty" drugs - modulation of the methylation machinery.

Authors:  Lisa Pleyer; Richard Greil
Journal:  Drug Metab Rev       Date:  2015-01-08       Impact factor: 4.518

5.  Preclinical studies of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in pediatric brain tumors.

Authors:  Marie Morfouace; Birgit Nimmervoll; Nidal Boulos; Yogesh T Patel; Anang Shelat; Burgess B Freeman; Giles W Robinson; Karen Wright; Amar Gajjar; Clinton F Stewart; Richard J Gilbertson; Martine F Roussel
Journal:  J Neurooncol       Date:  2015-10-30       Impact factor: 4.130

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.